GlassScriptPhysician profile
Diana E Moller
NPI 1477942639
$3,480.06
in general payments reported to CMS, 2019-2025
25 companies · $1,630 in 2025
The $1,630 reported for 2025 was more than what 88% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $80.81 · 2022: $38.10 · 2023: $819 · 2024: $912 · 2025: $1,630.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,356 · Education: $5.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,356.15 |
| Education | $5.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $828.34 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $516.30 | 2023-2025 | Breztri, Airsupra, Farxiga |
| Amgen INC. | $255.30 | 2021-2025 | Otezla, Repatha, Parsabiv |
| Ironwood Pharmaceuticals, INC | $221.38 | 2023-2024 | Linzess |
| Pfizer INC. | $184.53 | 2024-2025 | |
| Axsome Therapeutics, INC. | $177.54 | 2025 | Symbravo |
| Merck Sharp & Dohme LLC | $155.45 | 2023-2025 | Belsomra, Capvaxive, Gardasil 9 |
| Ardelyx, INC. | $152.26 | 2024-2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $149.99 | 2024 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $141.15 | 2023-2025 | |
| Novo Nordisk INC | $123.95 | 2023-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $103.59 | 2023-2025 | Jardiance |
| Sumitomo Pharma America, INC. | $84.96 | 2023 | Gemtesa |
| Fresenius USA Marketing, INC. | $70.21 | 2021-2024 | Velphoro |
| Astellas Pharma US INC | $52.31 | 2025 | Veozah |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $49.17 | 2025 | Vyepti |
| Vertex Pharmaceuticals Incorporated | $30.71 | 2025 | |
| Cequr Corporation | $26.24 | 2024 | Cequr Simplicity |
| Vifor Pharma, INC. | $25.17 | 2023 | Korsuva, Veltassa |
| Saluda Medical Americas, INC. | $25.10 | 2025 | Evoke |
| Esperion Therapeutics, INC. | $24.00 | 2023 | Nexletol |
| Akebia Therapeutics INC | $23.17 | 2021 | |
| Incyte Corporation | $22.89 | 2025 | Opzelura |
| Aurinia Pharma U.S., INC. | $19.39 | 2023 | Lupkynis |
| Glaxosmithkline, LLC. | $16.96 | 2025 | Arexvy, Shingrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diana Moller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.